Cell line · CVCL_0608
Papers48
1 to 20 of 48
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Bivalent CD47 Immunotoxin for Targeted Therapy of Lung Cancer. | Biomedicines | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Amphiregulin-mediated EGFR activation drives both intrinsic and acquired resistance to KRAS G12C inhibitors in KRAS G12C-mutant non-small cell lung cancer. | Oncogene | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Reconstruction of T cell infiltration in an osteosarcoma PDX-organoid interactive biobank for personalized immunotherapy. | Cell Rep Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| PARP inhibitors induce a senescence phenotype in non-small cell lung carcinoma cell lines. | FEBS Open Bio | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Cyclic di-GMP suppresses cancer metastasis by targeting proteasome 26S subunit non-ATPase 3 independently of STING. | Signal Transduct Target Ther | 2026 | Its Methods give the RRID and name the line | PubMed | |
| ANP32A-mediated histone 3 K27 acetylation is essential for sotorasib activity in KRAS-mutant non-small cell lung cancer. | J Biol Chem | 2026 | Its Methods give the RRID and name the line | PubMed | |
| RAS Mutation-Specific Responses to Paralog- and State-Selective RAS Inhibitors. | Mol Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Lipid Composition Alters Ferroptosis Sensitivity. | Cancer Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| CRISPR-Drug Combinatorial Screening Identifies Effective Combination Treatments for MTAP-Deleted Cancer. | Cancer Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| The G protein-coupled receptor GPR89A is a novel potential therapeutic target to overcome cisplatin resistance in NSCLC Calu1 cells. | FEBS J | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Impact of Co-mutations and Transcriptional Signatures in Non-Small Cell Lung Cancer Patients Treated with Adagrasib in the KRYSTAL-1 Trial. | Clin Cancer Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Improving PD-1 blockade plus chemotherapy for complete remission of lung cancer by nanoPDLIM2. | Elife | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Reduced representative methylome profiling of cell-free DNA for breast cancer detection. | Clin Epigenetics | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Tumoral and stromal hMENA isoforms impact tertiary lymphoid structure localization in lung cancer and predict immune checkpoint blockade response in patients with cancer. | EBioMedicine | 2024 | Its Methods give the RRID and name the line | PubMed | |
| FBXL16 promotes cell growth and drug resistance in lung adenocarcinomas with KRAS mutation by stabilizing IRS1 and upregulating IRS1/AKT signaling. | Mol Oncol | 2024 | Its Methods give the RRID and name the line | PubMed | |
| PI3Kβ inhibition enhances ALK-inhibitor sensitivity in ALK-rearranged lung cancer. | Mol Oncol | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Chromatin-bound RB targets promoters, enhancers, and CTCF-bound loci and is redistributed by cell-cycle progression. | Mol Cell | 2022 | Its Methods give the RRID and name the line | PubMed | |
| TNIK Is a Therapeutic Target in Lung Squamous Cell Carcinoma and Regulates FAK Activation through Merlin. | Cancer Discov | 2021 | Its Methods give the RRID and name the line | PubMed | |
| Quantitative Proteomics of the Cancer Cell Line Encyclopedia. | Cell | 2020 | Cellosaurus cites it | PubMed | |
| RUVBL1/RUVBL2 ATPase Activity Drives PAQosome Maturation, DNA Replication and Radioresistance in Lung Cancer. | Cell Chem Biol | 2020 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_0608/papers